Market Overview

Eli Lilly Announces Negative Results of Solanezumab Phase 3 Trial

Share:
Related LLY
Leerink Presents: Your 2017 Biopharma Catalyst Tracker
Carl Icahn's Track Record In Big Pharma
Scenarios For The Healthcare Bill - Cramer's Mad Money (3/23/17) (Seeking Alpha)

Eli Lilly and Company (NYSE: LLY) today announced that the primary endpoints, both cognitive and functional, were not met in either of the two Phase 3, double-blind, placebo-controlled solanezumab EXPEDITION trials in patients with mild-to-moderate Alzheimer's disease. However, a pre-specified secondary analysis of pooled data across both trials showed statistically significant slowing of cognitive decline in the overall study population of patients with mild-to-moderate Alzheimer's disease. In addition, pre-specified secondary subgroup analyses of pooled data across both studies showed a statistically significant slowing of cognitive decline in patients with mild Alzheimer's disease, but not in patients with moderate Alzheimer's disease.

Posted-In: News FDA

 

Related Articles (LLY)

View Comments and Join the Discussion!